Guidance issued for genetic testing in prostate cancer
17 August 2020

BRCA2 gene testing is recommended. For BRCA2 carriers, screening starting at age 40 years or 10 years before the youngest prostate cancer diagnosis in the family is recommended.

To address the shortage of genetic counseling, the authors endorse collaborative evaluation models between health care and genetic providers. Optimal pretest informed consent, posttest discussion, cascade testing, and technology-based approaches should be included in the genetic evaluation.

"Models of genetic evaluation that incorporate technology to enhance access to genetic testing, such as telehealth or use of videos for pretest genetic education, were also endorsed, along with key elements of informed consent," Giri said in a statement.

More information: Abstract/Full Text

Copyright © 2020 HealthDay. All rights reserved.